Letrozol Loxoprel (Letrozole)

Letrozol Loxoprel is an aromatase inhibitor used in hormone‑dependent breast cancer therapy.

• Early‑stage estrogen receptor‑positive breast cancer: reduces recurrence after surgery.
• Metastatic estrogen receptor‑positive breast cancer: slows disease progression.
• Adjuvant therapy for postmenopausal women: improves disease‑free survival.

• Letrozole selectively and non‑competitively inhibits the aromatase enzyme, blocking the conversion of androgens to estrogens. By lowering systemic estrogen levels, it deprives estrogen‑dependent tumor cells of a growth stimulus, thereby inhibiting proliferation of hormone‑sensitive breast cancer cells.

Letrozol Loxoprel may cause a range of adverse reactions.

Common Side Effects

• Hot flashes: sudden feeling of warmth and sweating.
• Arthralgia: joint pain or stiffness.
• Fatigue: persistent tiredness not relieved by rest.
• Nausea: mild to moderate upset stomach.

Serious or Rare Side Effects

• Severe liver injury: jaundice, dark urine, elevated enzymes.
• Bone fracture: increased risk due to reduced bone density.
• Pulmonary embolism: sudden shortness of breath, chest pain.
• Allergic reaction: rash, swelling, difficulty breathing.

Before initiating Letrozol Loxoprel, clinicians should consider several safety measures.

• Bone health monitoring: assess baseline bone mineral density and consider calcium/vitamin D supplementation.
• Liver function assessment: obtain baseline hepatic enzymes and monitor periodically.
• Cardiovascular risk evaluation: review history of thromboembolic events.
• Pregnancy avoidance: contraindicated in pregnant or nursing women; ensure effective contraception.
• Drug interaction vigilance: avoid concurrent use with strong CYP3A4 inducers or inhibitors without dose adjustment.
• Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Letrozol Loxoprel can interact with several medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Tamoxifen: antagonistic effect reduces therapeutic benefit.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may markedly lower plasma levels.
• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase exposure and toxicity.

Moderate Interactions (Monitor Closely)

• Warfarin: potential alteration of anticoagulant effect, monitor INR.
• SSRIs (e.g., fluoxetine): may affect hormone metabolism, observe for side‑effects.
• NSAIDs: increased risk of gastrointestinal irritation, advise caution.